「先駆け審査指定制度」の対象品目を指定しました｜厚生労働省
https://www.mhlw.go.jp/stf/houdou/0000162665.html「先駆け審査指定制度」の対象品目を指定しました｜厚生労働省
Open the dedicated viewer to inspect the saved page with archive metadata pinned above it, similar to archive wrappers such as Web Gyotaku.
This is a self-contained HTML copy with CSS and images embedded, so it still renders even if the original page disappears.
The dedicated viewer keeps the original URL and saved timestamp visible while you review the archived HTML.
This page announces the Ministry of Health, Labour and Welfare's designation of five pharmaceutical products under the "Breakthrough Therapy Designation System" on April 21, 2017. Out of 47 applications, five new drugs were approved. The system aims to accelerate development and approval of innovative medicines for serious conditions by reducing review periods from the standard 12 months to 6 months. Designated products include Olipudase alfa, aducanumab, DS-5141b, SPM-011, and nivolumab from companies such as Sanofi, Biogen Japan, Daiichi Sankyo, Stella Pharma, and Ono Pharmaceutical.
